“Improving prescription drug affordability for Medicare enrollees is the core of the Inflation Reduction Act, and the next cycle of negotiations will continue to strengthen Medicare for generations to come," Chiquita Brooks-LaSure, administrator of the Centers for Medicare & Medicaid Services, said in the news release.

The new Trump administration should seize the opportunity to change the Medicare drug price negotiation program by introducing floors.

Concern is growing among Democrats after President Donald Trump reversed some of the former president's executive orders, including efforts to reduce prescription drug costs for Medicare and Medicaid beneficiaries.

Experts suggest that most Americans will not experience immediate changes in their out-of-pocket health care expenses.

On its last weekday in power, the Biden Administration has chosen the next batch of drugs up for price negotiation in Medicare.

The Trump administration’s first drug pricing action — rescinding a Biden executive order encouraging Medicare to help lower prescription costs — is befuddling drug pricing experts.

One of those now-cancelled policies directed Medicare to investigate ways to slash drug costs, including the possibility of a $2 monthly out-of-pocket cap on some generic medications. Monday's actions also follow through on a key goal of Trump's first term -- weakening the Affordable Care Act.

President Trump rescinded a Biden-era Executive Order that would have lowered the copays for some drugs to $2 for Medicare enrollees.

As President Donald Trump’s health care agenda for a second term takes shape, it’s becoming clear that many Biden-era policies won’t make the cut.

On Day 1 of his second term of office, Trump rescinded Biden's Executive Order 14087, "Lowering Prescription Drug Costs for Americans." Trump's action ha